Clemens Kratochwil

Efficacy of [68Ga]Ga-FAPI-PET as a non-invasive evaluation method of liver fibrosis

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Deescalated²²⁵Ac-PSMA-617 Versus¹⁷⁷Lu/²²⁵Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients

1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with²¹³Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease.

Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT).

PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study

Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?

PSMA-GCK01: A Generator-Based^99mTc/¹⁸⁸Re Theranostic Ligand for the Prostate-Specific Membrane Antigen

Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas

Liver metastasis of a neuroendocrine tumor demonstrates intense uptake in PSMA-PET-but not its lymph-node metastasis and primary-tumor.

Repetitive Early⁶⁸Ga-FAPI PET Acquisition Comparing⁶⁸Ga-FAPI-02,⁶⁸Ga-FAPI-46, and⁶⁸Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions

Static and Dynamic⁶⁸Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74

Detecting and Locating the Site of Local Relapse Using 18F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.

68Ga-FAPI-PET/CT in patients with various gynecological malignancies

Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma

18F-labeled tracers targeting fibroblast activation protein

Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity

Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?

[¹⁵³Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma.